<SEC-DOCUMENT>0001193125-22-103702.txt : 20220413
<SEC-HEADER>0001193125-22-103702.hdr.sgml : 20220413
<ACCEPTANCE-DATETIME>20220413084600
ACCESSION NUMBER:		0001193125-22-103702
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20220413
DATE AS OF CHANGE:		20220413

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		22823748

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d343008ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Washington,
D.C. 20549 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:15pt; font-family:ARIAL" ALIGN="center"><B>SCHEDULE 14A INFORMATION </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Proxy Statement Pursuant to Section 14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="50%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9745;</FONT>&nbsp;&nbsp;Filed by the registrant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;Filed by a party other than the registrant</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99.7%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR BGCOLOR="#dae9f3" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Check the appropriate box:</B></P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Preliminary Proxy Statement</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY&nbsp;(AS PERMITTED BY RULE 14A-6(E)(2))</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Definitive Proxy Statement</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9745;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Definitive Additional Materials</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Soliciting Material Pursuant to Section 240.14a-12</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:arial" ALIGN="center"><FONT COLOR="#0a6db2"><B>AMGEN INC. </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>(Name of Registrant as Specified in Its Charter) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99.7%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR BGCOLOR="#dae9f3" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Payment of filing fee (check the appropriate box):</B></P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9745;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</P> <P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><B>No fee required.</B></P> <P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><B>Fee paid previously with preliminary materials.</B></P> <P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL"><B>Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</B></P>
<P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[Subsequent to this filing, Amgen Inc. sent the following summary communication to one or more
investors and/or proxy advisory firms for their consideration in making their vote recommendations.] </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g343008g86c77.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:12pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#0a6db2"><B>Amgen 2022 Proxy Statement Key Highlights </B></FONT></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:1%; margin-right:1%; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><FONT STYLE="font-family:ARIAL; font-size:9.5pt" COLOR="#0a6db2"><B>Execution of Our Strategy.</B> </FONT><FONT
STYLE="font-family:ARIAL">Innovation is at the core of our strategy. In 2021, we remained focused on our strategic priorities while navigating the ongoing impact of the pandemic. </FONT></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">We launched three medicines that address serious diseases &#150; <B><FONT COLOR="#0a6db2">LUMAKRAS</FONT><FONT COLOR="#0a6db2"><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP></FONT></B><B> </B>for the treatment of advanced <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, <FONT COLOR="#0a6db2"><B>TEZSPIRE</B></FONT><B><FONT COLOR="#0a6db2"><SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP></FONT></B><FONT STYLE="font-size:8pt"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></FONT> for the treatment of severe asthma, and an expanded indication for
<B><FONT COLOR="#0a6db2">Otezla</FONT><FONT COLOR="#0a6db2"><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></FONT></B><B> </B>for the treatment of plaque psoriasis across all severities (mild, moderate, and severe). </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">We completed strategic business acquisitions that complement our internal innovation, including <B><FONT COLOR="#0a6db2">Five Prime
Therapeutics, Inc.</FONT> </B>and <B><FONT COLOR="#0a6db2">bemarituzumab</FONT></B>, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antibody in oncology, and <B><FONT COLOR="#0a6db2">Teneobio,
Inc.</FONT> </B>and its proprietary bispecific and multispecific antibody technologies and portfolio of early-stage oncology assets. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">We entered into a collaboration with <B><FONT COLOR="#0a6db2">Kyowa Kirin Co. Ltd.</FONT></B> to develop and commercialize AMG 451, a
Phase <FONT STYLE="white-space:nowrap">3-ready</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> asset in inflammation. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:1%; margin-right:1%; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><B><FONT STYLE="font-family:ARIAL" COLOR="#0a6db2">Our Commitment to
Society.</FONT> </B>Our approach to <B><FONT STYLE="font-family:ARIAL" COLOR="#0a6db2">environmental sustainability</FONT></B>, <B><FONT STYLE="font-family:ARIAL" COLOR="#0a6db2">social responsibility</FONT></B>, and <B><FONT
STYLE="font-family:ARIAL" COLOR="#0a6db2">corporate governance</FONT></B>, or ESG, begins with our mission to serve patients and is supported by our long-standing focus on using resources responsibly to support the sustainability of our business.
</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">In 2021, we launched a new <B><FONT COLOR="#0a6db2">environmental sustainability plan</FONT></B>, our third since 2007, that includes
a target of achieving <B><FONT COLOR="#0a6db2">carbon neutrality</FONT></B> in our operations by 2027 (while also aiming to further reduce our water use by 40% and waste disposed by 75%).<FONT STYLE="font-size:8pt"><SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></FONT> </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">Since its inception, The Amgen Foundation,
Inc.<FONT STYLE="font-size:8pt"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></FONT> has contributed more than $375&nbsp;million to <FONT STYLE="white-space:nowrap">non-profit</FONT> organizations around the world that complement
Amgen&#146;s <B><FONT COLOR="#0a6db2">purpose-driven dedication to impacting lives</FONT> </B>in inspiring and innovative ways, including through four signature science education programs that, in 2021 alone, reached over 27&nbsp;million students
and educators worldwide. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">We increased our focus on <B><FONT COLOR="#0a6db2">diversity</FONT>, <FONT COLOR="#0a6db2">inclusion</FONT>, <FONT COLOR="#0a6db2">and
belonging</FONT></B>, including by adding an <B><FONT COLOR="#0a6db2">ESG goal</FONT></B> to our Company performance goals for our annual cash incentive plan, working to improve the diversity and representation of racial and ethnic minority
populations in clinical trial research, and aspiring to double our supplier diversity spend and triple our Black-owned business spend in the U.S. by 2023.<FONT STYLE="font-size:8pt"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></FONT>
</P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:1%; font-size:12pt; font-family:ARIAL"><FONT COLOR="#0a6db2"><B>Voting Matters and Board Recommendations </B></FONT></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:1%; margin-right:1%; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">We are sending this summary in support of Amgen&#146;s Board of Directors&#146; recommendations for our 2022 Annual
Meeting of Stockholders to be held on May&nbsp;17, 2022. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #0a6db2; BORDER-TOP:1px solid #0a6db2; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #0a6db2; BORDER-TOP:1px solid #0a6db2">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:1px solid #0a6db2; BORDER-RIGHT:1px solid #0a6db2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #0a6db2; padding-left:8pt"><B><FONT COLOR="#0a6db2">FOR each Director Nominee</FONT></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #0a6db2">&nbsp;</TD>
<TD VALIGN="middle" STYLE="padding-bottom:3pt ;"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Item 1:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #0a6db2; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Election of 12 directors to serve on our Board
until the 2023 annual meeting of stockholders.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #0a6db2; BORDER-TOP:1px solid #0a6db2; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #0a6db2; BORDER-TOP:1px solid #0a6db2">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:1px solid #0a6db2; BORDER-RIGHT:1px solid #0a6db2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #0a6db2; BORDER-BOTTOM:1px solid #0a6db2; padding-left:8pt"><B><FONT COLOR="#0a6db2">FOR</FONT></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #0a6db2; BORDER-BOTTOM:1px solid #0a6db2">&nbsp;</TD>
<TD VALIGN="middle" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #0a6db2"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Item 2:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #0a6db2">&nbsp;</TD>
<TD VALIGN="middle" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #0a6db2; BORDER-BOTTOM:1px solid #0a6db2; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Advisory vote to
approve our executive compensation.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #0a6db2; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #0a6db2">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #0a6db2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #0a6db2; BORDER-BOTTOM:1px solid #0a6db2; padding-left:8pt"><B><FONT COLOR="#0a6db2">FOR</FONT></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #0a6db2; BORDER-BOTTOM:1px solid #0a6db2">&nbsp;</TD>
<TD VALIGN="middle" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #0a6db2"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Item 3:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #0a6db2">&nbsp;</TD>
<TD VALIGN="middle" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #0a6db2; BORDER-BOTTOM:1px solid #0a6db2; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Ratification of
Ernst&nbsp;&amp; Young LLP as our independent registered public accountants.</P></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:1%; font-size:11pt; font-family:ARIAL"><B><U><FONT STYLE="font-family:ARIAL" COLOR="#0a6db2">Item&nbsp;1:</FONT> Our Board recommends &#147;<FONT
STYLE="font-family:ARIAL" COLOR="#0a6db2">FOR</FONT>&#148; the election of the 12 director nominees.</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:1%; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><B>Our Board consists of a <FONT STYLE="font-family:ARIAL" COLOR="#0a6db2">group of highly qualified leaders</FONT> in
their respective fields. It includes <FONT STYLE="font-family:ARIAL" COLOR="#0a6db2">three women</FONT> and <FONT STYLE="font-family:ARIAL" COLOR="#0a6db2">two diverse directors</FONT> and has <FONT STYLE="font-family:ARIAL" COLOR="#0a6db2">strong
refreshment practices</FONT>, with seven new directors appointed since 2015, and an average Board tenure of ~6 years. </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">Many of our directors have: </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#150;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">Senior leadership experience at large companies and have gained significant and wide-ranging management experience. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#150;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">Public company experience, an understanding of corporate governance practices and trends, and bring a unique perspective to the Board.
</P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#150;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">Extensive scientific and healthcare expertise relevant to our industry, including pioneering scientific research in the areas of
oncology and cardiology and experience leading important academic institutions. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:1%;border-bottom:1px solid #666666; width:22%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="font-size:5pt" COLOR="#666666">(1)&nbsp;</FONT></SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="justify">Being developed in collaboration with AstraZeneca plc. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="font-size:5pt" COLOR="#666666">(2)&nbsp;</FONT></SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="justify">Carbon neutrality goal refers to Scope 1 and 2 emissions. Reductions take into account only verified reduction
projections, and do not take into account changes associated with the contraction or expansion of the Company and are measured against a 2019 baseline. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="font-size:5pt" COLOR="#666666">(3)&nbsp;</FONT></SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="justify">A separate legal entity entirely funded by Amgen Inc. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="font-size:5pt" COLOR="#666666">(4)&nbsp;</FONT></SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="justify">Measured against a 2019 baseline. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; padding-bottom:12pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</P></div>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g343008g52x10.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em">


<IMG SRC="g343008g94b80.jpg" ALT="LOGO">
</P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:12pt; margin-left:4%; margin-right:1%; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><B>We are committed to corporate governance best practices, informed
by stockholder engagement, and overseen by our highly experienced and independent Board. </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">Our <B><FONT COLOR="#0a6db2">lead independent director</FONT></B>, Robert A. Eckert, has substantial and specific duties and has been
elected by our Board to serve as the lead independent director in 2022 subject to his <FONT STYLE="white-space:nowrap">re-election</FONT> to the Board by stockholders. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">We have a <B><FONT COLOR="#0a6db2">highly independent Board</FONT></B> (11 of our 12 director nominees are independent) and only
independent Board members serve on key standing committees.<FONT STYLE="font-size:8pt"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></FONT> </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">We have a long-standing practice of <B><FONT COLOR="#0a6db2">stockholder engagement</FONT> </B>throughout the year and at our Annual
Meeting. Since our 2021 annual meeting of stockholders, we have engaged in governance-focused outreach activities and discussions with stockholders owning ~52% of our outstanding shares. In addition to these governance-focused outreach activities,
we have more than <B><FONT COLOR="#0a6db2">doubled our participation in investor events and engagement sessions</FONT></B> since 2017. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; margin-right:1%; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><B>Our Board has a history of responsiveness to stockholder feedback. </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; margin-right:1%; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">In addition to our stockholders electing our Board annually by majority voting and having rights to act by special
meeting, written consent, and proxy access, as well as our robust clawback and recoupment mechanisms, we have expanded and enhanced a number of our disclosures, including data from our annual Consolidated
<FONT STYLE="white-space:nowrap">EEO-1</FONT> Report,<FONT STYLE="font-family:ARIAL; font-size:8pt"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></FONT><FONT STYLE="font-family:ARIAL; font-size:9.5pt"> mapping our ESG reporting to the
Sustainability Accounting Standards Board (SASB) standards for our industry, and reporting on drug pricing practices. </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:1%; margin-right:1%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B><U><FONT STYLE="font-family:ARIAL" COLOR="#0a6db2">Item&nbsp;2:</FONT> Our Board recommends &#147;<FONT
STYLE="font-family:ARIAL" COLOR="#0a6db2">FOR</FONT>&#148; the advisory vote to approve executive compensation.</U> </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; margin-right:1%; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><B>We have implemented compensation best practices, including: </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">A substantial <B><FONT COLOR="#0a6db2">majority of our Named Executive Officer, or NEO, compensation is performance-based</FONT></B>
(including 80% of total target equity, of which 50% are three-year performance awards and 30% are stock options). </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">Our equity incentive plan provides that our equity awards are subject to a <B><FONT COLOR="#0a6db2">minimum vesting period</FONT></B>
of no less than one year for 95% of equity awards granted. Our grants generally vest over four years, with no vesting in the first year and vesting in three approximately equal annual installments on the second, third, and fourth anniversaries of
the grant date. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">We have robust <B><FONT COLOR="#0a6db2">stock ownership</FONT></B> and<B> <FONT COLOR="#0a6db2">retention guidelines</FONT></B>.
</P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">We have strong <B><FONT COLOR="#0a6db2">recoupment mechanisms</FONT></B>, including a <B><FONT COLOR="#0a6db2">clawback
policy</FONT></B> that permits recapture of past cash or equity compensation awarded to our executive officers and a <B><FONT COLOR="#0a6db2">recoupment policy</FONT></B> that permits a determination that cash incentive awards are not earned and to
facilitate the forfeiture and cancellation of unvested or unexercised equity awards (granted after December&nbsp;31, 2020). </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; margin-right:1%; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><B>Executive compensation is aligned with our business strategy and is
performance-based. </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">We <B><FONT COLOR="#0a6db2">pay for performance</FONT></B>, and pay outcomes reflect the achievements of our NEOs against our short-
and long-term performance. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B><FONT COLOR="#0a6db2">&#149;</FONT></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="justify"><B><FONT COLOR="#0a6db2">76%</FONT> </B>of our Chief Executive Officer&#146;s, or CEO&#146;s, 2021 target direct
compensation and<B> <FONT COLOR="#0a6db2">71%</FONT> </B>of our other NEOs&#146; target direct compensation was <B><FONT COLOR="#0a6db2">based solely on our Company&#146;s performance</FONT></B>. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B><FONT COLOR="#0a6db2">&#149;</FONT></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="justify"><B><FONT COLOR="#0a6db2">92%</FONT> </B>of our CEO&#146;s 2021 target direct compensation and<B>
<FONT COLOR="#0a6db2">84%</FONT> </B>of our other NEOs&#146; target direct compensation<B> </B>is &#147;<B><FONT COLOR="#0a6db2"><FONT STYLE="white-space:nowrap">at-risk</FONT></FONT></B>.&#148; </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">Our Compensation and Management Development Committee, or Compensation Committee, approves annual Company goals that are designed to
focus our NEOs and all of our staff members on delivering our financial and operational objectives to <B><FONT COLOR="#0a6db2">drive annual performance</FONT></B>, <B><FONT COLOR="#0a6db2">advance strategic priorities</FONT></B>, and <B><FONT
 COLOR="#0a6db2">position us for longer-term success</FONT></B>. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#150;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">To build the infrastructure to support achievement of our 2027 environmental sustainability plan and further embed diversity, a sense
of belonging, and inclusion into our culture, our Compensation Committee added an <B><FONT COLOR="#0a6db2">ESG goal</FONT></B> in 2021 focused on two areas: an environmental goal and social responsibility goal. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:1%;border-bottom:1px solid #666666; width:22%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="font-size:5pt" COLOR="#666666">(5)&nbsp;</FONT></SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="justify">Key standing committees of the Board include the Audit, Compensation and Management Development, Corporate
Responsibility and Compliance, and Governance and Nominating Committees. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="font-size:5pt" COLOR="#666666">(6)</FONT></SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="justify">Beginning with our Consolidated EEO-1 Report filed in 2021. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; padding-bottom:12pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </P></div>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:18pt; margin-left:4%; margin-right:1%; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><B>We executed on our strategic priorities in 2021 and delivered strong performance while continuing
to provide uninterrupted supply of our medicines globally. </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">As noted above, we <B><FONT COLOR="#0a6db2">launched new products</FONT></B> (LUMAKRAS, TEZSPIRE, and the expanded indication for
Otezla) and, <B><FONT COLOR="#0a6db2">to augment our pipeline and research capabilities</FONT></B>, we completed <B><FONT COLOR="#0a6db2">several strategic transactions</FONT></B> (Five Prime Therapeutics, Inc. and bemarituzumab, Teneobio, Inc., and
a collaboration with Kyowa Kirin Co. Ltd.). </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">We executed <B><FONT COLOR="#0a6db2">key clinical studies</FONT> </B>and advanced our <B><FONT COLOR="#0a6db2">innovative <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> pipeline</FONT></B>: </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#150;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">Advanced <B><FONT COLOR="#0a6db2">bemarituzumab</FONT> </B>into Phase 3 for the treatment of patients with human epidermal growth
factor receptor 2 negative FGFR2b-positive gastric and gastroesophageal junction cancer; </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#150;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">Expanded
<B><FONT COLOR="#0a6db2">KYPROLIS</FONT><FONT COLOR="#0a6db2"><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></FONT></B> U.S. prescribing information to include its use in combination with DARZALEX FASPRO<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP><FONT STYLE="font-size:8pt"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></FONT> and dexamethasone for patients with multiple myeloma at first or subsequent relapse; and </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#150;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify"><B><FONT COLOR="#0a6db2">Progressed our early innovative pipeline</FONT> </B>forming <B><FONT COLOR="#0a6db2">7</FONT> </B>product
teams,<FONT STYLE="font-size:8pt"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></FONT> initiating <B><FONT COLOR="#0a6db2">4</FONT> </B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT>
studies, and advancing <B><FONT COLOR="#0a6db2">4</FONT> </B>programs through our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">early-to-late</FONT></FONT> stage portal. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">We advanced our <B><FONT COLOR="#0a6db2">biosimilar programs</FONT></B> (with 11 biosimilars in our current portfolio) and <B><FONT
 COLOR="#0a6db2">Phase 3 studies</FONT></B> underway for <B><FONT COLOR="#0a6db2">three</FONT></B> additional biosimilars. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">The U.S. Food and Drug Administration approved (in January 2022) our latest <B><FONT COLOR="#0a6db2">U.S. biomanufacturing
plant</FONT></B> featuring innovative technologies in Rhode Island, expanding our manufacturing capacity while also delivering <B><FONT COLOR="#0a6db2">environmental and cost efficiencies</FONT></B>, and we announced plans to invest approximately
<B><FONT COLOR="#0a6db2">$1 Billion to build two additional U.S. plants</FONT> </B>(in Ohio and North Carolina) featuring innovative technologies that support our 2027 environmental targets, while expanding our access to diverse talent. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; margin-right:1%; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><B>Our strong cash flows and balance sheet allowed for significant investment
in 2021 for long-term growth, while simultaneously providing substantial returns to stockholders. </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B></B><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">We <B><FONT COLOR="#0a6db2">invested in excess of $8.2 Billion for long-term growth</FONT></B>, including $4.8 Billion in our research
and development activity, $2.5 Billion for acquisitions, and $880 Million in capital projects. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B></B><FONT COLOR="#0a6db2">&#149;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; " ALIGN="justify">We<B> <FONT COLOR="#0a6db2">returned $9 Billion to stockholders</FONT> </B>($4 Billion in dividends and $5 Billion in share
repurchases). </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:1%; margin-right:1%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B><U><FONT STYLE="font-family:ARIAL" COLOR="#0a6db2">Item&nbsp;3:</FONT> Our
Board recommends &#147;<FONT STYLE="font-family:ARIAL" COLOR="#0a6db2">FOR</FONT>&#148; the ratification of the selection of Ernst&nbsp;&amp; Young LLP as our independent registered public accountants. </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:1%; margin-right:1%; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Our Audit Committee periodically considers whether there should be a rotation of our independent registered public
accountants. Each year, the Audit Committee evaluates the performance of the independent registered public accountants and determines after such evaluation whether to <FONT STYLE="white-space:nowrap">re-engage</FONT> the current independent
registered public accountants. Based on this evaluation, the Audit Committee believes that the continued retention of our independent registered public accountants is in the best interests of the Company and its stockholders. </P>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #0a6db2; BORDER-TOP:1px solid #0a6db2; BORDER-RIGHT:1px solid #0a6db2; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #0a6db2; BORDER-RIGHT:1px solid #0a6db2; BORDER-BOTTOM:1px solid #0a6db2; padding-left:8pt; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-right:0.50em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Our 2022 Annual Meeting of Stockholders will be held solely by remote communication via the internet. While you will not be able
to attend the Annual Meeting in person, stockholders will, to the extent possible, be <U>afforded the same rights and opportunities to participate at the virtual meeting similarly to how they would participate at an in-person meeting</U>.
Stockholders will have a meaningful opportunity to ask questions.</P></TD></TR>
</TABLE> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:1%;border-bottom:1px solid #666666; width:22%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="font-size:5pt" COLOR="#666666">(7)&nbsp;</FONT></SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="justify">DARZALEX FASPRO is a registered trademark of Janssen Biotech, Inc. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="font-size:5pt" COLOR="#666666">(8)&nbsp;</FONT></SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="justify">Formed when a molecule has been judged to have the potential to be safe and effective in humans. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; padding-bottom:18pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</P></div>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g343008g52x10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g343008g52x10.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MZ=..LZLE"$5\4YOX80BM92=M(I-OH@M92EM&G%RD^D8QU<I/:,8K=NR74UZ
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M6T-=$U>UO&"VDD>F:4?$K&VO)84,M[!<1EKFSMUIX=NEC<)B':U"OA)P;O\
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MC)<LE[2G*T(N5*<IN*<6I-3/KZL#4* "@ H \^^&7_(N:E_V4'XM?^K5\9T
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MUU;2QSV]Q!+\4_&3Q3031,R2PNC*RNC%6!!!(- /\CTB@ H * "@ H * "@
MH * /P]_;Q_Y.!U'_L5O#/\ Z335_3/A;_R2='_L)Q/_ *5$_DOQ@_Y+2O\
M]@F%_P#2)'QG7Z*?EP4 ?LS_ ,$[?^2*>*/^RI:W_P"HGX)K^=/%W_DI,#_V
M+*/_ *E8P_J/P2_Y)3,/^QM7_P#4/ 'WK7Y8?L1\M_MH_P#)M'Q)_P"Y._\
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M\19G7H5\SP%.I3J8_%3IU*<\52C.$X2JN,H2BW&49)J2;333/WUK^53^R H
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MPC!+E@I2B*M4KR4>6-2?,EHEI"$&U"/NPYI1E-I.3DY.I)J4Y1C[Q6184 %
M'GWPR_Y%S4O^R@_%K_U:OC.@&>@T % !0!X)^U#_ ,F_?%7_ +%:?_TIM:^J
MX(_Y*S(O^PF/_I,CX[Q!_P"2+XB_[!)?^EP/Y[*_K0_BL* /4O@=_P EK^#_
M /V5+X?_ /J6:17B<3?\DWQ#_P!BS'_^HM4^AX2_Y*OAC_L;9=_ZF43^CROX
M\/[D"@#\/?V\?^3@=1_[%;PS_P"DTU?TSX6_\DG1_P"PG$_^E1/Y+\8/^2TK
M_P#8)A?_ $B1\9U^BGY<% '[,_\ !.W_ )(IXH_[*EK?_J)^":_G3Q=_Y*3
M_P#8LH_^I6,/ZC\$O^24S#_L;5__ %#P!]ZU^6'[$?+?[:/_ ";1\2?^Y._]
M3_PK7W'AQ_R6>3?]S?\ Z@XD_/O%3_D@\]_[DO\ U8X0_!6OZF/X["@#WO\
M9>_Y.!^%7_8TV_\ Z37-?+<;_P#))Y[_ -@TO_2HGV/A_P#\EGP[_P!A<?\
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M?_29']"=?R4?VH% '\]G[4/_ "<#\5?^QIN/_2:VK^M>"/\ DD\B_P"P:/\
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M+O#?_0#F?_@G"_\ S8?&?\00XJ_Z&.4?^#\9_P#, ?\ "AOVB?\ HWWXJ_\
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MX'_$$.*O^ACE'_@_&?\ S '_  H;]HG_ *-]^*O_ (*]#_\ FAH_XB[PW_T
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MASQ9K(:!;SPUJD3FX-N=T:[ _P VSYW;R/J>7M9GU=02% !0 4 % !0 4 %
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MM!1WE6]K3I^P2_GY:L*W9T8UI*[HU$J,7[37P6FTZ^U6'Q/JLME8065ZS1>
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M%WH6B7UR;R^T;2KR\,$5J;J[T^TN+DVUO)/+!;F>:%G\B.6ZN72/=M5KB4@
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M7AZ+SI;+5-=U6&Z,5K!%'8$R^)-6B>VTY+*SDB>V$ELSZ?9R6L2RO,G"=/\
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M_0=;KX3C3?+?^YC_ -PGTW"W\?,O^O>$_P#2L4?5U?#'V(4 % !0 4 % !0
M4 % !0 4 ?*/[4'^K\$_[_B+_P!!T2ON>"M\R_[E_P#W,?'<4_Q\M_Z]XK_T
MK"GR77W9\R<#\4],U#6/AQXUTG2;:2[U*_\ #NI6EC:PKNEGN9K=DBB1=R[F
M+$#&Y?J*X,SHU,1@ITJ4>:4JE#1KF7*J]*4KQNN:*BFY*ZO%-7.S+ZD*&+I5
M)OEA#GN[V^Q)*SL[.]DG9V9X.OAGXC^!CXFM?#>G/9"\\4:%+<77@G1K'3-%
MF\)Q^']96"Z\.Z#=1:N+#7QX@^P6^JJR73R0I;RQE8F9X/(5',<'3JTL/"5+
M_::LI.A""IN+PR6'E0I3510A*<$J\-6JZ]Z<:$W(]-5<%B)49UI*7+AXJ*K3
MDYJHL0G6C6J1=/F:I2DZ,DXKD=DG5BHO5G\+_$B7Q7_PDK7.K6FN7_AWX0>'
M[W5K/3/#C_V=;7.M:N_Q"725O+"^%@88([6YE19KB(/?9;[0L%L+;JEA<7'&
MUJM.I4IO$5Z%.I.,:+<</'"3E.-.4J<FJ:Q2BE=RM*SU=Y/!8C"_5*5)PA.-
M#ZW4A"4JBO4=:E&A*HHRBI3]@Y)M*-U%I<J;3EDN/C<LOC2$W6MPBU>_CTF:
M/1=#U& VT7BW3TT.XTDK;6CS27'@];XWP0ZG*DDS31017,$5G<YJ>;NGB7)S
MIU%4A9*G!J/^T5+JE:/,Z3H<B<E&O4C'DDKU75BM.7*XRPW*H2CR.]YRBV_J
MJO[2[:52.)U@FZ4':4)-T^6HFV]G\5)I[/Q1Y7B'3M;M_#/A"QN;5QH=\-:-
MM\1]834H=09M"M?+1O"ER+SRX+73[B%+R,3'[1 U52AF"Q*Q-JE-SCDD*L'[
M.2G'ZSBXXUS:A'WJ-"M[1NFJ:3DGR/E45E4E@U3E07).,99E*G-<\7!O#8>6
M&Y4YO25>GR+G=3F4'9VDV[ 7XTQR_;/[5\12;5M[X::VF>&!9M-'\2I=/;3"
M5T<7'V1O CBX<"X$IVK,LJL-M&'6:Q^K3JU:LG_PENI"4**C^]Q$Z>8)\L(R
M2HT%&>DERR?-=[%5?[.M6C"G3C;ZY&$E*K>T,.I862O-IN5>\=59KW6K!I4_
MQLNY-1@U*XUBP:3Q'X?MII(=-T)XM/L)O&5Q#JTWA^>73@DVGKX3,3EIXM1V
M!()//^T-<1!85YM.%*.(E4IRE4HJJU&E>'[G$O$*#<+>R]JL.H/EE;3EJU.:
M?(8A9;3<G0C":C"HX+FG9ZT52<US74TO:N23A?WDX02@WN> ;'Q['XUCO_%M
MUXFN;9_">J:5$UW%IB:4USI7C?7(;*YNXK&RA%MJ5UX<71+H.@C$_GRD@B-4
MAVRN&-CB*]3&2JR=?!X%I24%3C5IO$1KQBHQ7+-.5.I:_O>UJWO&%*-+'&SP
MSH0IX:%.*I8FO9Q<N=TYTZ,J=W*3O!252%^GLX;.<W4]ZKV3S H * "@#F_%
MYU9/#6KG0I;N#55MA]CGL+*#4;N%_-C$DD-E<S1+<%8?,)56:3:"88Y90D4G
M+C/;+#R]A*4:BE3UC'G:C[2'/[N]N3F4G!2J1C>5.$YJ,'T854_;0]JE*"4M
M)2Y5?DERZ[7YK64FH-V4Y1@Y27BVDVOQ*U'6-(-T-<T6UOX]'L-9UJ*VT0ZM
M-ING_P#"Y)T\Z^N_#MO/';M,W@ET@N;&.>V&I*K 7%Q=2S>?&&.G9WJ8=R@G
M)Q5)S<H4JJAS2=)7O+V<K.$&N;DE&-YP/1G+!4Z$[<E:=*51TX-U%!.<\M3M
M!5'9J'UJ+:FU+V?,I2C&E:O/?_%XZ7;2-_PE,?B!T\*&\M[/2M$.BV_A^70M
M D\57Q=K!Y/^$CCUIO$"):VS37(98A#9O;A&::D\QZ>VC)S7M5&$/9TZ/N<K
MHODE.4V]*D5SS2=>T4XX=H4,!&<HITI4XJHJ4I3ESSJ*55153WE%1Y.649/D
MIMJES2UK(["].L3_  XM/^$D\.:AXRU5M5=8-*O=/>)9H5U:\71[_P 1:789
M-UIUMIHMKB6&6U\V8Q1&6S@NFV0;UU4>"POML.\37<K-3I\T(-QJ156M1@VI
M\M-WY+).NX-*@TI4>>E[..+K>QK+#T8Q5G&=I.RIN5.E4DDXN51-*5]*7,N:
MM&_M>5T/PG?V&K:!'%I>KW-[:WOA272/$U[IC6/]E>%["PNXO$FD-YK,VAP2
M737\<>E%VW)JUCL\U;5WM\\/AYT\11BHU+TYK]_->^\(LKAAX0G/2\WBXNI*
MCO&M)U^16YEK6KQG2K-RA&$H2O1@]/K+QKJN<8KHJ#@E5ZP@Z5[M1E=U/P5_
MQ3<NCZC9^))]+C^(^L:M)Y.GV7C"^NK"2RU(6-WJ-CXCBU'^U;.34)[9B3:W
MCI((7V1Q1O-;Q5PG^Q82C.G4:H5\;-15.&(UG7QOL?:QK*?-&4*L9*<DWS.,
MY5(/]XJAB;8K$5:<J<95:&%C?GE02<:>$=14W2<.5Q=.4>5.,>52C&,M(2]C
M\*1ZA#X8\.PZK8VFF:G#HFEQ7^G:?%#;V-A=QV4*3V=I!;N\4%O#(K1I'$[H
MBH%1F4 GVJ?.J=/VD8PJ<D.>,7>$9\JYXP;U<(RNHMZN*39Y53D56K[*3E3Y
MY\DI:2<.9\DI+2TI1LY:+WF]$;]40?6G[+_^K\;?[_AW_P!!UNOA.--\M_[F
M/_<)]-PM_'S+_KWA/_2L4?5U?#'V(4 % !0 4 % !0 4 % !0 4 ?$_[9^I7
MNEZ1X"N+&;R)FU'786?RXI<QM;::Y7;-&ZCYHT.0,\=>3G])\.:%*OB,TA5C
MS1C3H-*[6JE47V6GLV?FWB)BJ^#AE-3#5/9SE+$Q;Y8R]UJ@VK24EO%:VOH?
M G_"8>(_^@C_ .2EC_\ (M?JG]G8/_GS_P"3S_\ DC\P_MS-/^@K_P ITO\
MY6'_  F'B/\ Z"/_ )*6/_R+1_9V#_Y\_P#D\_\ Y(/[<S3_ *"O_*=+_P"5
MA_PF'B/_ *"/_DI8_P#R+1_9V#_Y\_\ D\__ )(/[<S3_H*_\ITO_E8?\)AX
MC_Z"/_DI8_\ R+1_9V#_ .?/_D\__D@_MS-/^@K_ ,ITO_E8?\)AXC_Z"/\
MY*6/_P BT?V=@_\ GS_Y//\ ^2#^W,T_Z"O_ "G2_P#E8?\ "8>(_P#H(_\
MDI8__(M']G8/_GS_ .3S_P#D@_MS-/\ H*_\ITO_ )6'_"8>(_\ H(_^2EC_
M /(M']G8/_GS_P"3S_\ D@_MS-/^@K_RG2_^5A_PF'B/_H(_^2EC_P#(M']G
M8/\ Y\_^3S_^2#^W,T_Z"O\ RG2_^5A_PF'B/_H(_P#DI8__ "+1_9V#_P"?
M/_D\_P#Y(/[<S3_H*_\ *=+_ .5A_P )AXC_ .@C_P"2EC_\BT?V=@_^?/\
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M_P#H(_\ DI8__(M']G8/_GS_ .3S_P#D@_MS-/\ H*_\ITO_ )6'_"8>(_\
MH(_^2EC_ /(M']G8/_GS_P"3S_\ D@_MS-/^@K_RG2_^5A_PF'B/_H(_^2EC
M_P#(M']G8/\ Y\_^3S_^2#^W,T_Z"O\ RG2_^5A_PF'B/_H(_P#DI8__ "+1
M_9V#_P"?/_D\_P#Y(/[<S3_H*_\ *=+_ .5GWW^QAJ5[JFD>/;B^F\^9-1T*
M%7\N*+$:VVI.J[88T7AI'.2,\]>!C\K\1:%+#XC*H4H\D73K-J[>O-375M[)
B'Z?X=XJOC(9M4Q%3VDXRPT4^6,?=2KM*T5%;R>MKZG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g343008g86c77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g343008g86c77.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MI2E)M^*:'_P3Y\;:5K6D:G)X_P#"LL>FZII]^\26&KAY$L[N*X:-"R8#,L9
M)XR:^EQ7BYEE?#8C#QRG%1=:E4IINI2LG.#BF[/97/D<'X'YOA<7A,3+.\'*
M.'K4JCBJ=:[5.<9-*ZM=I61[%X&_9$\3^%/C\/C!<^+=!N]+7Q9XL\0_V1!:
M:@E_Y'B&/6D@M_-D3R?-A.J1ESG!\IL=17SN:>(6!QW"?^KL,OKTZ_U7"X?V
MLITW3YL.Z+E*R]ZTO9.W757/JLG\+\PRSC;_ %IJ9GAZF&6-QN*]A&%55.7$
MK$*,>9KEYH^V7,]M';H9GQL_8LUCXD_%+5_'_ASQ1H&@V6LOI=Y>:;>V=^\W
M]I6EI;VM[<(UJACQ<FU29NYDEE8\MSMPSXE8?),BP^48S U\74PJJPA4A."7
MLY2E*$6I._N<SBNBBHI;'/Q=X2XK/^(\3G> S'#8*CBW1G.E4IU'+VM.$83D
..N1<O[SD4GU<W)O<__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g343008g94b80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g343008g94b80.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H ^(?VAA:W7QB\':?J=]X-M]-/PQ\47BP>/\
MX@>(/AYX=?4(?$N@PP31:IX>;SKC5UAFN%CMV&TPM=29#0KG]&X2]I3R#-ZM
M"GBY5XX_ P4L#@:&/Q*@Z&-<E[*O[L:3<8N<T[J:IQVDS\WXR5*>>\/4<1/"
M1P\L'FLG''8ZME^&<X5<L4&ZU!.3J14IJ$6FN651]->)\*_&7QK8_#[P9IT'
MCG2O":Z-\&M=\=_V_P"/;%=9N/'6LZ'XGUC18_#NGW>H:O \VC);Z=;R1W4+
MSZA/::GITH"LQW^KF/#^73S;-,1+*ZN/=3-,%@EA<%+V'U2EB<'2KRQ-6%*E
M-1KRG-P=-QA0IXBG7BW))6\7*N(LPIY-DV%AFU'+(QR[,\8\;CD\3#%5,%CI
MT(8:A5K5H2J8:%.U15N:>(JX66'E%PDYM[R_M&^/;WQ)X>O+6;3['2;OQE\+
M?".L>%+O1M%MAI]UXSM/#DFOV$E]?^+HO$=[K5E)K=P\4UIX?73XULPLDTQ2
M6N=<'952P^*HS52K5C0SBO1Q4:U5\\,OGBXX>I&G3PDL)"C/ZM&-15L6J\G-
MN$(*5.^KXVS>K4PV)INEAX0ED5/$8*5&C'DJYI# SQ%*I4K8R&+G5A'%RG0>
M&P<Z,(T[5IS<:MNA?XL_%)/#3Z_>>*?"FCV'B+XV:A\*]+U2Z\-C[+X(T72O
M%/BS3[CQ)K5S/K,4&I7ES#I>GZ=!%*EI;QR>5+))(]PRKP4\BR66*PN%A@\3
M7K4<CAFU6G'$>]C*T\'AZL<)0A&E*5-*<ZE><TZE1P4X0A%04GZE;B#/:>%S
M3%2QF%H8>/$%7):$Y8>\<%0AF5;#O'8F<J\(5.6E&%"$&J<%5=.I4G-3E"-?
MPUK6J7O[._[3&IS>(H=<O8->^-YM?$.CO-!8W(MM'W6]]HJ_;;EK*R=AYT$<
M5S,D8D'ER. '9X_#4*/$W M&&#EA*<Z.2<^'K)2J1Y\:U*%9\D.>27N2<J<9
M22]^*=XHRW%5ZO#7B%5GCH8RI1JYW&&(H7C3?LLJI\LZ2]I4]FN9<UH5)1C-
MR<)-69Q^CZAX9T74=!A^$_B%]:MKSX">/=:^*^EV/B[5O%.B6E]9^&]+E\.7
M^IK+K-U'HVNR:X^HV^R"2VG,33+M50#7IXZCC*]'.'GF$6'C0SG!4LIJSPM+
M#59*>*K1Q%.C)4J<JU%894YOFYZ:DH2UDSQ\KJX##5N'%D.-=>MB,GQM7.*-
M/%U<522A@J$J%;$TY5JD,/7^N.5.FXJG4FI5H/W8I+L?#_Q6^(-A+\./ -J+
M(WWCWPM\&->\%2QZ>T_V/PN?#ES>_%..5[B9_M5S8P: _P!GDN96=6\160=G
M906X<=D>53EGV9S4W3R/&9W2QT7/E=6HJJCE/*HQ7(JU:M[.:IQ2:P]1I).R
M[<LS_-J>&X8RR$J<*O$66\/U,NE[/FC1]R+SI24FY5%A\)36(@ZDWRNO"+G)
MI)\YX7_:#^*NKVD.NSS>'C#K'ACXAZM/X=G?P+:77A:Y\-Z#K.J:9_9-I9>/
M;[Q%K$EI?:=;6FH6^JZ):-B:6;$ C$9Z,?PKDF%]KAH*O*6$J8",,3!8V<,2
ML16H0J>U<L%#!T:=6%6<L/.CBIV<80;J.4I*<MXMSS&3HXB;H4HXJ6/C/ U'
M@:=3"K#4\2X*DHX^IC:V(HSHP6*IU<)",E*M.*I1A",I?$WQN^+?A#2/!FL:
MUXG\+2VFK^ M-^(>LMHOAW1)-1TR+5GLOL^GW?AK6_&NGWVL>'K>V2Z$NH:)
M(UX]Q-)BVA2.*.1X/AK(,;C<TPF&P6)C+"9A++J7MJ]94ZLH2JJ4XXBA@J\*
M&(D_9JG2Q,?81IQ3E5G*4W'+%\4\18'*\FS#%8W"\N.R[^TZWL,/AW5HTW1P
MTH0>&Q./P\\30A>M/$5,+/ZPYSC&G1IPC'FG\4>*O$A^)%TND>)SX4TT?M'_
M  ^T.]GB%[&FI6&K_".TU2.+55N]3BB-H)EDC-BT4<,KS6[R1^=; RQEN7X1
M9106(P?UVL\ASJK"#Y)>SJX?-723I<M.3]HU9QJJ4I02FH/EG95F>9XQYUF#
MPV-6 H4\\X9A*HE4A[2CBLIIU91K*56"5/FE[U-QBIKE51.2N_5OA!\3/'/C
M;QA=>$];:R2?X<Z3K^G?$F6VT\0)>^,)/%U_I/A1;%F)%K:3^&=$O-6=(B<C
M4[4$A<!O#SS)LLR_+(9GAHS]GG$\+++HRJ-NG0CA(U<?S_SRI8JK3PT7+;DG
MUV^@R+.LTQV;SR?$3@ZN1+'1S.<::2JSGBE3RAPMI25?!PJXJ26KO!-16_BW
MQ*U7XEP7/[8@\,R^'F\-Z?I^C'5)]7UC7[77=*C;X8:7/*WA:WT^RFM5F*-+
M*/-GM@9B"3@EJ]_)J&3/">'?UZ->.*K8O$*DJ-*A*E5DLW<8K%2J3C/DORQ]
MV,VJ?,DM$G\_GE?/(8_Q/672P_U2AEF'E5]O5Q$*M&/]@RG*6$5*,H*I;GFN
M9P3JJ#;W:+?XH>)/#6O?$.STW4-'\.B^\>? OPA=>,M:AN=1L/#6F>(OAW_:
M%]KNI6U]JD=GY@GM8K.)F:T@\R_C:<LP!;IJY'@\9@LEG5IU<0HT^)\5'"4G
M&G/$5,'CXPI8:E*%-U%S*3J22]I/DIR5-1Z>9A.(,=@LQXBITJE'#<M+@G#/
M&5E.I##0S#+W[;%5XSJQIR5-I0@[TH^TJ0=9S29=TWQQX_\ B%XG^%:V/CC1
M8]2B^)OQT\+V7BG1M%:X\/ZCHWAWPD/[/U&/0?[7$-_YL6^:!IKRXCC:=) T
MZH/,Y*V6Y7E& SNI4RRLJ4LFRG&5,+6K6KTZU;,(*=+V[I<U/E:4)VI0FXJ4
M6J<I/E]*&:YIFV99#2IYK0E4I9_FN"I8O#T6\/4H4<EKSC4=!5G"JWS2G"]6
M=)5>2:=2G%*7%^)?B9XE\2>'X?&FJ-;MJ=_^S1)J-]96SW]IH\VJ6_QE\/Z1
M)?):6U\DD$CQ1NPV3AE\TH&V?*?4P62X'!XZ66X=2C0AQ)@(0G+DG6C3JY5B
MJWL^>4&I*+DEK%I\J;3>IY&:YWF-?!RS#$SA/$PX6SYU(P52G0J5<+FV!PRJ
M^SC4O%RC!O2=X\\HQDD>M?\ "[O&<OQ$M=*_X2OPE9P7'QXE^%\GPX?2$;Q5
M:^%M/M[EE\4M?OJAGV:B8X)=[6"VX2]MA!,&#+-\_2X;R[^R%7>!Q567]A5,
MT_M"-5K#+%-V6#Y%3Y+T;-22J^T<X3YH<NL/I\1Q/F,,YGAHYA@Z$*>?87*5
METJ2>+EA9QI2EC5/VW/:O[2\&Z"I1I2@E/VO\3B_AWXQ^)6F^#_!VC_\)9:W
M&E>//"_Q_GT[S-'G?6O#5_X)UO4[JQOTUIM6,VJ33-=2Q[&2W2%$@6(!HM[]
MV<Y?D]7$YG7^HSAB,H7#TYN-51I8B&,P]"%2E[%4N6DE%)\ZE.4JCG*6DE!<
MG#>/SFE2RF@L=">%S?%\2X>$)T93JT*F%QF/JT:WMG6O5Y9P</9.,(*BJ<(\
MLHRG+&@^/'Q'\,>$/AW/_P )?H^J:)8?"/P7XDU_5XHO#GB/Q-)JE_YPOCXG
MT77/&NF:MJ5C;VULMI+=Z*US=R7-M=RS%9V^SIWU.%\FQN:YW3_L^K0KSSC$
MX3#T?]HP^%5**@X?5ZV'P6(HT:M2<_:4Z>)C"A&C*E&'-!.H_'H<69W@<DX=
MJ?VE1Q&'CDE+&XJO_LV)QOM54JQDZ^'Q6/PU:OAZ<*7)5J86<\5.O"M=1DE!
M?HW!*L\$,Z9V311RIE'C.V1 ZY210R'!'RL 1T(!%?D$X.G.=-Z.$G%ZIZIV
M>JNGMNFT^A^TTJBJTJ56.L:D(R6C6DDFO=E9K?9JZV>I+4&@4 % !0 4 % !
M0 4 9&HZ!H6L/%+J^B:1JDD"E()-1TVSOGA1B&98GN87,:E@"0I R,UO1Q6*
MPRDL/B:M!2MS*G4G"]MKJ+5[7TOL<]?"83%<GUG"TL1[._)[6G"IRWM?EYXO
MEO97M:]EV%OM!T/4TLX]2T;2M033G673TOM.L[M+"2,*J26:W$+BU=510&CV
MD!1CH**6*Q-"525'$5:,JJ:FX5)P<T]6I.+3DGU3N.KA<+7A3IU\-2K0I-2A
M&=.$XPDE9.*DFHM+1-6:6Q'+X;\/3WLVI3:#HLVHW @6XOY=+L9+V=;62*6U
M$UT\!EE$,MO \89CL:&,K@H"''%XNG3C1ABJL*,')QA&I-0BY*49-1344Y*4
ME)I:J4D]&R9X/!U*DJM3"T9U9*,93E2@YN,)1E&+DXMM1E&,HINRE&+5FD3R
MZ+H\]C<:9/I.F3:;=R2RW6G2V%K)8W,LTQN9I+BT>(Q32/<$RLSH2SG<26YJ
M8XBO"I3JQKU(U:*BH34Y*<%%<L5&2=XJ,?=BDU9:+0MX?#RIU:,J%.5*LY2J
M0<(N$W-\TW.+5I.4M9.2;D]7=CX])TJ"TGT^'3-/AL+H2BZLH[*VCM+@3QB*
M83VRQB.821*J-O4[E !R!BE*O7E4A5E6G*I3LXS<Y.46I<RY9-WC:3<E9JTM
M5J$,/0ITYTJ="G"E--2A&$5"2<5!J44DFG!*#37PI1V5B*RT+0]-M[BTT[1M
M*L+6[!6ZMK+3K2UM[D,AC87$,$*I,#&2I#@\$CH:JKBL37E"=;$5:TZ?PRG4
MG-QUO[KDVXZZZ6U)HX3"X:,J>'PU*A"?Q1ITX0C+2WO**2>FFO0L)IFFQ26<
ML>GV4<NG6[6FGR):0))86KI'&]M9NL8-K;M'%$ICC*J1&H(PHQ+K5FJJ=6;5
M>2E43E+]Y)-M2FK^])-MIRNTVWNRUAZ$?8\M"G'ZM%QHVA%>RBTHN-.R]R+C
M&,6HV344MDBG%X<\/07=]?PZ#HT-]JD<D.IWL6EV,=WJ,,N/-BOKA8!)=QO@
M;EE9PV.0:MXO%.E3HO$U71H-2ITW4GR4VMG"-^6+71Q2:(6$PD:U3$+"THUZ
MRY:E14X*I..B<9SMS25DE9MK1=@N_#OA^^_L_P"W:%HUY_9.S^ROM>F65Q_9
MGE^6(_[/\Z!OL>T11;?)V8\M<?=&"GB\71=5TL35I.O?VKC4G%U+WO[1IKGO
M=WYK[ON*I@\'5C1A5PM&I##6]E&=*$E2LDE[-.+4+**2Y;625MD33Z+HUUYW
MVG2=,N/M-U;WUQY]A:R_:+VT5$M;N;S(CYMU"D4:QRMET$:A2 HQ,,1B*?)[
M.O4A[)2C#EG)<D9MN<8V:Y5)MN25DVW>]RIX7#5/:^TP]*?MG!U.:G%\[II*
M#G=/F<%&*@Y7Y5%6M9'/>#_ ND>#)?$MW8W.I:EJ?B[77\0:]J^L3V]QJ%Y=
M_9+73[2#?:VEM%%8V=A9V]O;PI$-BHQ8O)([OUX[,Z^.I8"A4A3HX?+:/L*%
M*DI1A%.<JM2;4I3;J5:DY3J2OJ[)*,8QBN3 Y7A\#B,RQ=.4ZN*S2O&O7JU7
M%R?LZ4*%&E'EC!1I4*5.-.E&S:5W*4IRE)],^EZ9(+]9-.L775 JZFKVENPU
M%5A%NJWX:,_; (%$8$N_" +]T8KC5:M'V5JLX^P=Z5I27LWS<S=/7W'S>]>-
MO>UW.UT*+]M>C!_6(\M6\(_O8J/(HU-/?BH>Y:5UR^[MH<QXH\":/XFTJ[TO
MSK[P\;VYL+JZU'PTUEI]]<R:8 EK%?K<6-S::O9"$"(VFHVMW R!08_D4KV8
M/,\1@J]*M:.*5!5%"GB.>=./M=9RA:<)TIN7O>THSIU%)<RG>]^/%Y7A<70K
MT$GA'B%24ZN'4*=64:-E3A-N$H5:<8)T_95H5*3IRE!PY61^"_A[X=\"Z9'I
MVF1W%_,NJZQKLVL:RUO>ZQ=:SKTKRZMJ,EU';0QV\UP&$;):0V\0B18UC"+B
MJS'-L7F555*KC1IQHTL/&C14H4HT*'\.GRN4I2497G>I*<G-N3DV9Y;D^#RR
MFX4E*O4E7JXF5:ORSJNO57).HG&$(4_W:5*,:,*<(TDH1BHZ'1?\(_H/E"#^
MQ-(\A;4V*P_V;9^4+(W"W9LQ'Y.T6INE6;RL;/,4/C<,UR?6\4I<WUFJI<RG
M?VD[\\8\L9WO?FC%N*ENHNR=CM>#PCCRO"T7'EE"SIPMR3DISA;EMRSDE*4=
MI22;3:N>>7'P<\.WGC2V\::AK'BG4)[+78O$MCH=]J=K/H=GK5O97%C9W4).
MG#4FM[6*[N7M["34I+*!YW:*W3.*]6EQ!BZ&7SR^CA\-24Z$\-*O&G)5G1J2
MC*I%_O/8\T^6,9UO8^WE!*,JC/)K\/83$YA3S"MB,3/V5>EB(T'4C[!5J$6J
M33]G[?V=.3=6-#V_U=5FZGLN8]*BTG2K?[+Y&F:?!]A%T++RK*VC^QB^;?>B
MUV1C[.+AN91'M\P\ODUX\J]>7/S5IR]HH*=YR?,J:M!2N_>4$K03ORK:Q[,:
M%"G[/DHTX>R<Y0Y817)*HVYRC9+E<W*3FU9R;=[W9FOX0\)O]AW^%_#K?V6S
M-IF_1--;^SF>=KIVL<VW^ALUTS3$Q;,R,7/S$FMEC\?%U''&UXNLDJC5:HG-
M*/(E.TO>2BN5*5[1T6FA@\NR^2I1E@</*-"4I4TZ--JG*4N>4H)QM"4I^])Q
MLW+5ZZG15R'8% !0 4 % !0 4 ?*?QD\.?%V]\<1:OX/TK7_ !#IJ:+X,B\)
M0:5XSG\,:#X:\1Z;XIUJ]\97OC#3[7Q]X:EU.TU31+CPQ'!<K;>)1%#HNI6K
M:9B_*WSH>[6CSJR=>BY3EK!89*U2G&'O6J1ESS=Z<E64J=-RI^SYXU6L\.XP
M^)4L0N5*TW7:A["3G[O[O24+*<)49<U7][S*"Y:6?]L:?2-7:.UALM9MAXRO
M;&"-/AK):WNJ6/A^]NO">CZ=<W%^_P#Q1^H^(XM,LT:_M[7588)[MKR]C+Q3
MV;PW+;"/$:6A3=9?WW5RV-5/EOI&G+,YPE3:7+3HQ<7-1>(JHH7Q$8/E7M;4
MI*[M2Y,PY9)27Q7CEZG&:?O2J.-H.4:5+6[;]K./Q3XGUS2+'6'A+76CV=M;
MZI\-UTQ-#B\>>)+G2+OP/I6I:HT,FJ-X//A(WUUXIMTN"\FLQ6TB[+..&(-Q
MI27VY_5K\R3:G3P^9>ULHM15#ZU/!I*,H5JF'Y>>2J0E*G+LY4KVBJ:K:1;2
MM.IEO+S.SDZRHPQMKJ5&G63Y%*G-*KV?B;0?CMKWPP\60ZR=;U#Q/=_$3X>3
MZ9X<\'ZOX=\&W@\ :'XW\&ZCXNBT37;+Q#82VEUJ?A^'Q1')%J'B,2&*.*VC
MD1I6:YTFJ,:F$:4ITXXC$2JI2U5'V^*AAHW_ ':E%8=8:H_=YW*<N=)KV<'2
M=OK";4;X-0I.4;KZS+ 0YYVM-Q:QLJD$_@BH1E"\;3EBVFB_M%^'M.T._P##
M^G:G?/HVF_%G5;7PQXH\7:5J^KSV,WQ1\"ZSX ^'.NZ[J/B*]@O/$%Y\.;3Q
M;ID6MM=ZC%IL[0B;5"@,E]BO:Q<K\M2:HX6%_AA*;K8R-25E%23PU"IA)5)*
M,7B:E&6L^>125&4*D>9TN;$<T%:\H0CA+2OK-<E7&1E:',_9T:RY84W32IV!
M'^UK_:=]I-Q=V@M2OP]LXO$VEV7@$Z=]GGU;X7Q>/-9TJTU.Y%[:ZQ:V%Q\5
MY1;:A8WUK)!9Z2+1%NH@-7WC&ESRBYR5.-2:4FESRIP5=4I123C'VD(T'64H
M\T<1.?L[4%RK)-J*DX)2E2G)4TW:%1TY-4YO1MTZ[C"$H2Y98>*=1NM)RAR6
MNZ;^UMK.B:G9&+Q!::EIU_XL_LOQ#I>M?#?1-8U/3WTNW;1X]/T2ROGTW3!-
M=V\EK#_:=WJDRM>R327%F%1XHH.*^JU*J<'%4O:PC:3]W&Y5.II*\+RPZS"T
M%=)4_9RJU552J:M4TL3"+4E>7L9232UPN9PA=Q2G[M9X!N7NW<^=4H>SER>\
M?![Q#\0_$6M_$=/%LXF\.^%?$D_A/PM>'3K2QF\026U_JFM7NM2/:P1QRBRT
MG6_#7AF;[-_H[:GX0UN5,B9=E147AZ=5V52K*:48WY?94I.E"LN:TE]:E&=7
MDG\%/V7+92;EA*\:SI1NX4X0E)RY>;VE6$9RHRY?=OA_A4H-J7M+2;E#3W:H
M*"@ H * "@#ROXW:+XO\1_"KQGH?@&:\M_%^I:;#;:'/8:F^C7<-RU_9M+)#
MJ4>J::]J5M5G):._M'90R)*K,#2Y;U,,K\L(XG"NHW=I48XFE*MS*,HRE'V2
MGS0C)2G&\8ZM&M*48>V<E=_5\5&"LOXLL-5C1M>,E&7M7#EDTU"5I.R39X!:
M:-^TOX)\&6^@^'[+5M?\20_$CQ+>76JCQ+H&HZ!/X3CDL9] ATRW^)?B76]>
MM_#%_8M.DMA=:X-4T_4$O%@NGT_[(TVM)QE4RU5?=I126)O9O_?H*I=TXQ<D
ML).M/#RC>4:=.C3K1E5NC&:Y5CN364K.ARW7_,%)1LIMI-8J%.->,K1E*I4J
M4FH;6[I_VGC'!J']@ZY>ZM877BY;JU@U?X9Z18H]W936FDOX/9-2N(K_ $*(
MFVGL_P#A*K"XOEE27[6BJZ^7G2TITO:7C.5"G&H]'*-65?*G6=K.GRP@LQ=)
MQM)TH1A*2J3BZFL^1>WY;-1K.5)>]RRI1I9DJ=Y.TU.3> 55/W%5G*<8NG"2
MAYWK_@O]JOQ/X;\6IJ,7B:PU^Z\/6>H:3+I'C+P]I$MWXBT:PN_#$6F6\&A^
M+K&STN34=/UZZU>=H+K3;5KO1(&$L$GDA+7LXTZ-U>2KX:=2*YM%*&12Q+BW
M.#=*G/#YI25%S3DJS<7:HIROFIJ3Y=$J&)IQ<DOYLY^K\W+%I5G[7*Y*KR24
M5"TK.FU';LO /[0?]KZ1:V&H?$KP]H"R?#ZXE:X\0>#S'I=QIGC'QS<>,;EK
M+6/B/X[O;F>;0-0\*;(+C6-8L[J.*=)K56M;6U@F[BDXM.=-5Y132:UR_'TZ
M5-KEBFGC'0<G)SE#VE*<*L53E[&(^R4)1DK.3L]_^@O*Y\ZES-J2P\,8DH\D
M;0J1=-RK7KZ_E?M?:BGA>?5+"WB\_P 0_"W_ (2/1;:^\$V-CINEV-C\$=:\
M<:I#?:9JR:A.Z>)A\7K%[5+ZZBGM+%(XK2>*>T>[UDJ4:]3V;3IJ.,E3YN;E
MC.-7DP<&DN9QG1G*4W)2:<(:TYIJ:2BJ4$V^?V;C.R7,VZ6.4I*_NQDJD,#R
M\MDG5F[V4G2ZZ]T_XZ^(_@!XTTS6K/Q/'\4[RSL([.UM-6\%>'+][_[/H,^O
M6_A'7/"GB"VMK+0!J*ZY#IEQJE_8ZE]F$8O9"Y663.2I*6#<5.5&&)PTJD6U
M&L\/#$TI555Y7&G[1T544XT9>SE&T8W;=RDW&>*YW"+EA\3&FTG*DJTJ%>%%
MT^:+J<JJ.DXRJQYHR]Y\J5H\U9Z'^T3X?>35O"NCZX^EZ>OQ$UGP[X,\9^-=
M)U_71I_]O_!J[T'P!K>NW_BO5;>34M:L=)^+ L-2;4=2AT=-5L(I;ZVC3[/(
MDY1HQORU*Z48O2T6IXK&ZMJ*?-AL-5PLI62=65'V?-4NY,4:3]LKNDI5J<J;
MM=QC# \LW:\O<JXR-G'=0JNHH0:7)H"/]K7^T[[2;B[M!:E?A[9Q>)M+LO )
MT[[//JWPOB\>:SI5IJ=R+VUUBUL+CXKRBVU"QOK62"STD6B+=1 :O<8TN>47
M.2IQJ32DTN>5."KJE**2<8^TA&@ZRE'FCB)S]G:@N50FU%2<$I2I3DJ:;M"H
MZ<FJ<WHVZ==QA"4)<LL/%.HW6DY0Y+7=-_:VUG1-3LC%X@M-2TZ_\6?V7XAT
MO6OAOHFL:GI[Z7;MH\>GZ)97SZ;I@FN[>2UA_M.[U296O9)I+BS"H\44'%?5
M:E5.#BJ7M81M)^[C<JG4TE>%Y8=9A:"NDJ?LY5:JJI5-6J:6)A%J2O+V,I)I
M:X7,X0NXI3]VL\ W+W;N?.J4/9RY/>/@]XA^(?B+6_B.GBV<3>'?"OB2?PGX
M6O#IUI8S>()+:_U36KW6I'M8(XY19:3K?AKPS-]F_P!';4_"&MRID3+LJ*B\
M/3JNRJ5932C&_+[*E)TH5ES6DOK4HSJ\D_@I^RY;*3<L)7C6=*-W"G"$I.7+
MS>TJPC.5&7+[M\/\*E!M2]I:3<H:>[5!04 % !0 4 133PVL4D]Q-%;P0J7E
MFFD2**)%ZM)(Y"HH]20*:3;22NWLE_D)M15V^5+KLCA[SXJ?##3@S:A\1_ 5
M@J*69KSQAX>M0BJI8LQGU%0JA5))/8$]J[*>6YA5_A8#$5+?RT*LO+I%G'4S
M++J$>:KC\-1CWG7I06U]Y22V5_0AT[XN_"?5W6+2/B?\/-4D8X2/3O&OAN]=
MB#MPJ6VIN2<\<#K5ULIS7#*]?+,502ZU,/6@O_)H(QH9UD^*LL+FV#Q'-LJ6
M*H5+]-.2;OVT/0(Y(Y422)TDC=0Z/&P='1AE61E)#*1R"#BO/M;3:W0]->6W
M0?0 4 % !0 4 % !0 4 % !0 4 9^I:MI6C0"ZU?4]/TJVW!!<:E>VUC!O/
M42W,B)N.1QG-7"G4J/EIPE.7:*;?W),B=2G2CS5)QIQVO)J*OLE=M(XB\^,7
MPBTX'^T/BG\.+ *0I^V>./#-J Q) !\_5%P2588_V3Z5VT\IS6K94LLQ=2^R
MAAZTME?3E@]EKZ'#7SC*,*F\3FF#PZC:[J8FC32N[*[E-6N]%YZ&UHWC_P "
M>(GCB\/^-?"6NR2DB*/1O$FC:F\A&,B-+*\D+D9'0'K6-; XW"W^L82MA^7?
MVE*=.W_@458VH8_ XJWU7&T,1?;V5:G4VM>W))[77WHZVN4ZPH * "@ H *
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M?_DP_P"$Y\$_]#AX6_\ "@TG_P"2Z/[,S+_H7XG_ ,$5?_D _M?*O^AGA/\
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MC7,_^PO$?^GIG+5W'GA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M+WJ4JCD[,^'XCP&0X+A?*<QPF >'Q^>JE"G"JJBE3HY?+$0KXRFI<B:S*-7
M58SY%3E:NJ4(V?+\TU]L?FX4 % '4^.?^1U\8?\ 8T^(/_3M=UPY9_R+<O\
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M.MA\-6I95KF56A2R^#QE!2K*O+$J,\1%)U,(HK"U&[TZT92:I0G*JIPAW5>
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5 % !0 4 % !0 4 % !0 4 % '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
